Traffic Lights - Latest Updates

Last updated: 31/03/2020

Other updates on this site
Drug Name Classification Clinical Indication Comments
ALIROCUMAB (Praluent®) (NEW) Black Adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels

Not yet reviewed

BUDESONIDE (1mg orodipersible tablet) (Jorveza®) (UPDATED) Red Eosinophilic esophagitis
BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) (UPDATED) Red Substance misuse

Turning Point are piloting this in a small number of patients. If a patient is admitted to hospital contact turning point for advice about alternatives:

0116 3732117 – Direct dial to prescribing team

0116 3732108 – Direct Dial to Clinical Admin

0330 303 6000 – Main Switchboard

CANNABIDIOL(Epidyolex®) (UPDATED) Red Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in combination with clobazam

In line with NICE TA614 and NICE TA615

CEFEPIME (Renapime®) (NEW) Black Antibiotic

Not yet reviewed

CEFOXITIN (Renoxitin®) (NEW) Red Antibiotic
CLADRIBINE (UPDATED) Red Relapsing-remitting multiple sclerosis

In line with NICE TA616

CYANOCOBALAMIN (NEW) Black Vitamin B12

Initially for new patients only. Implementation date for all patients September 2020 to allow time for review.

DORAVIRINE (Pifeltro®) (NEW) Red HIV
ECULIZUMAB (Soliris ®) (NEW) Black Treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease

Not yet reviewed

ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (Trikafta®) (NEW) Red Cystic fibrosis as part of managed access programme

Also known as VX-445/VX-661/VX-770

ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) (NEW) Red In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder

Subject to LPT Managed Entry Requirements

GLYCOPYRRONIUM LIQUID (Colonis) (NEW) Amber Simple Sialorrhoea in paediatrics
HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN (CMVIG) (Cytotect CP Biotest®) (NEW) Black Clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy

Not yet reviewed

LEVOFLOXACIN NEBULISER SOLUTION (Quinsair®) (UPDATED) Red Chronic Pseudomonas lung infection in cystic fibrosis (adults)
MEXILETINE (Namuscla®) (NEW) Black Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders

Not yet reviewed

NALOXONE nasal spray (Nyxoid®) (UPDATED) Red Opioid overdose

Turning Point Only

PARATHYROID HORMONE (Natpar®) (UPDATED) Red Post-trial continuation of treatment of chronic hypoparathyroidism when standard therapy alone is inadequate.
PATISIRAN (Onpattro®) (NEW) Black Hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

Not yet reviewed

PENTOSAN POLYSULFATE SODIUM (Elmiron®) (UPDATED) Red Bladder pain syndrome characterised by either glomerulations or Hunner’s lesions

In line with NICE TA610

PRASTERONE PESSARY (Intrarosa®) (UPDATED) Amber Simple Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms
RIVAROXABAN (Xarelto®) (NEW) Amber Simple Preventing atherothrombotic events in people with coronary or peripheral artery disease

In line with NICE TA607

ROMOSOZUMAB SOLUTION FOR INJECTION (Evenity®) (NEW) Black Severe osteoporosis in postmenopausal women at high risk of fracture

Not yet reviewed

SODIUM ZIRCONIUM CYCLOSILICATE (Lokelma®) (UPDATED) Red Hyperkalaemia

In line with NICE TA599.

Implementation date 4th December 2019.

SOLRIAMFETOL (Sunosi®) (NEW) Black Improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy

Not yet reviewed

TESTOSTERONE GEL (Tostran ®) (UPDATED) Amber Simple Testosterone deficiency in menopausal women (unlicensed)

Tostran brand only. As per NICE NG 23

TEZACAFTOR AND IVACAFTOR (Symkevi ®) (NEW) Red Cystic Fibrosis
UPADACITINIB (RINVOQ®) (NEW) Black Moderate to severe active rheumatoid arthritis, responded inadequately to, or who are intolerant to one or more DMARDs.

Not yet reviewed

USTEKINUMAB (Stelara®) (NEW) Black Ulcerative Colitis

Not yet reviewed

VONICOG ALFA (Veyvondi®) (NEW) Black Von Willebrand disease

Not yet reviewed

VORETIGENE NEPARVOVEC (Luxturna®) (NEW) Black Vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations

Not yet reviewed

VSL#3 (UPDATED) Black Probiotic
ZANAMIVIR SOLUTION FOR INFUSION (Dectova®) (NEW) Red Treatment of complicated and potentially life-threatening influenza

Other Updates on this Website

Recent documents from LMSG and TAS


About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more